The full income statement, balance sheet, and cash-flow statement for Bio-Rad Laboratories Inc. (BIO), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 2.58B+0.7% | 2.57B-3.9% | 2.67B-4.7% | 2.80B-4.1% | 2.92B+14.8% | |
| 1.34B-2.8% | 1.38B-3.4% | 1.43B-9.0% | 1.57B-4.3% | 1.64B+13.9% | ||
| Cost of revenue | 1.24B+4.7% | 1.19B-4.6% | 1.24B+0.8% | 1.23B-3.9% | 1.28B+16.0% | |
| Research & development | 276M-6.9% | 296M+19.6% | 247M-3.7% | 257M-1.4% | 261M+19.7% | |
| Selling, general & administrative | 844M+3.7% | 814M-3.3% | 842M+1.7% | 828M-5.6% | 877M+9.8% | |
| Restructuring | — | — | — | 0.00-100.0% | 75.6M | |
| Amortization of intangibles | 23.8M+12.3% | 21.2M-10.9% | 23.8M-4.4% | 24.9M-12.3% | 28.4M+3.3% | |
| Provision for credit losses | 1.40M | 0.00 | 0.00-100.0% | 7.50M | 0.00 | |
| Operating income | 47.2M-82.5% | 269M-20.4% | 338M-30.0% | 483M-3.5% | 500M+18.8% | |
| Interest expense | 49.0M+0.2% | 48.9M-1.0% | 49.4M+29.7% | 38.1M+2356.5% | 1.55M-92.9% | |
| Other non-operating income | 90.3M+0.0% | 90.3M-15.2% | 107M+138.3% | 44.7M+66.9% | 26.8M+9.3% | |
| Gain (loss) on equity securities | 900M+133.9% | -2.66B-112.2% | -1.25B+75.9% | -5.19B | — | |
| Pre-tax income | 996M+142.5% | -2.34B-175.6% | -850M+81.9% | -4.70B-186.3% | 5.45B+10.8% | |
| Income tax | 236M+147.3% | -498M-134.2% | -213M+80.2% | -1.08B-190.1% | 1.19B+8.2% | |
| 760M+141.2% | -1.84B-189.4% | -637M+82.4% | -3.63B-185.3% | 4.25B+11.5% | ||
| Net income to common | 760M+141.2% | -1.84B-189.4% | -637M+82.4% | -3.63B-185.3% | 4.25B+11.5% | |
| $27.85+142.6% | -$65.36-199.5% | -$21.82+82.1% | -$121.79-186.5% | $140.83+11.4% | ||
| EPS (basic) | $27.87+142.6% | -$65.36-199.5% | -$21.82+82.1% | -$121.79-185.4% | $142.61+11.3% | |
| Weighted-avg shares (basic) | 27.3M-3.4% | 28.2M-3.4% | 29.2M-1.9% | 29.8M-0.2% | 29.8M+0.2% | |
| Weighted-avg shares (diluted) | 27.3M-3.3% | 28.2M-3.4% | 29.2M-1.9% | 29.8M-1.4% | 30.2M+0.2% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 2.91B-4.1% | 3.03B-0.6% | 3.05B-3.5% | 3.16B+58.7% | 1.99B-7.0% | ||
| Cash & equivalents | 530M+8.5% | 488M+20.9% | 404M-7.0% | 434M-7.8% | 471M-28.9% | |
| Short-term investments | 1.01B-14.1% | 1.18B-2.2% | 1.20B-11.3% | 1.36B+239.8% | 399M+21.3% | |
| Accounts receivable | 461M+1.8% | 453M-7.5% | 489M-1.1% | 495M+16.8% | 424M+1.0% | |
| Inventory | 741M-2.5% | 760M-2.6% | 781M+8.5% | 719M+25.7% | 572M-8.0% | |
| Prepaid expenses | 137M+11.3% | 123M-12.4% | 140M+12.7% | 124M+13.8% | 109M+20.4% | |
| Other current assets | 27.7M-9.8% | 30.7M+17.6% | 26.1M+10.6% | 23.6M+134.0% | 10.1M-7.1% | |
| 10.6B+12.9% | 9.36B-23.9% | 12.3B-8.9% | 13.5B-24.1% | 17.8B+37.2% | ||
| Property, plant & equipment | 540M+2.2% | 528M-0.2% | 529M+6.1% | 499M-2.5% | 512M+4.1% | |
| Operating lease right-of-use | 170M+5.9% | 161M-17.6% | 195M+7.6% | 181M-11.6% | 205M+1.3% | |
| Goodwill | 580M+41.2% | 411M-0.7% | 414M+1.7% | 406M+17.0% | 347M+19.0% | |
| Intangible assets | 174M-40.6% | 294M-8.4% | 321M-3.5% | 332M+30.8% | 254M+27.3% | |
| Long-term investments | 6.10B+26.1% | 4.84B-37.1% | 7.70B-12.8% | 8.83B-38.6% | 14.4B+50.5% | |
| Other non-current assets | 103M+0.8% | 102M+7.4% | 94.9M+0.3% | 94.6M-9.2% | 104M+20.1% | |
| 517M+10.5% | 468M-10.5% | 523M-8.1% | 569M-16.5% | 681M+7.8% | ||
| Accounts payable | 129M+5.5% | 122M-15.4% | 145M+7.1% | 135M-4.9% | 142M+1.8% | |
| Deferred revenue | 48.9M+2.3% | 47.8M-6.5% | 51.1M-2.1% | 52.2M+2.7% | 50.9M+19.7% | |
| Short-term & current debt | 1.30M+8.3% | 1.20M+140.0% | 500K+7.5% | 465K-4.9% | 489K-72.8% | |
| Current lease liability | 36.1M-13.4% | 41.7M+3.2% | 40.4M+11.2% | 36.3M-0.3% | 36.4M-0.2% | |
| Other current liabilities | 142M-3.7% | 147M-8.9% | 162M-4.7% | 170M+32.6% | 128M-2.4% | |
| Finance lease liability (current) | 500K+25.0% | 400K-20.0% | 500K+0.0% | 500K+0.0% | 500K+0.0% | |
| 3.12B+11.7% | 2.79B-21.4% | 3.56B-8.5% | 3.89B-5.5% | 4.11B+33.0% | ||
| Long-term debt | 1.20B+0.1% | 1.20B+0.1% | 1.20B+0.1% | 1.20B+11291.6% | 10.5M-14.2% | |
| Non-current lease liability | 146M+10.9% | 131M-20.6% | 166M+7.7% | 154M-12.7% | 176M+0.5% | |
| Operating lease liability (total) | 182M+5.0% | 173M-15.9% | 206M+8.4% | 190M-10.6% | 212M+0.3% | |
| Finance lease liability (total) | 9.20M-4.2% | 9.60M-5.0% | 10.1M-4.7% | 10.6M-3.6% | 11.0M-4.3% | |
| Finance lease liability | 8.70M-5.4% | 9.20M-4.2% | 9.60M-5.0% | 10.1M-3.8% | 10.5M-4.5% | |
| Deferred tax liabilities | 1.06B+29.5% | 818M-44.6% | 1.48B-16.7% | 1.77B-42.2% | 3.06B+47.6% | |
| Other non-current liabilities | 199M+12.4% | 177M-9.1% | 195M-0.5% | 196M+7.5% | 182M-7.5% | |
| 7.45B+13.5% | 6.57B-24.8% | 8.74B-9.1% | 9.62B-29.7% | 13.7B+38.5% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Additional paid-in capital | 476M+2.8% | 463M+3.1% | 449M+0.4% | 447M+1.3% | 442M+2.9% | |
| Retained earnings | 8.18B+10.2% | 7.42B-19.9% | 9.26B-6.4% | 9.90B-26.8% | 13.5B+45.9% | |
| Treasury stock | 1.01B+30.8% | 772M+22.1% | 633M+140.0% | 264M | — | |
| Accumulated other comprehensive income | -189M+64.9% | -538M-60.2% | -336M+28.0% | -467M-165.9% | -176M-162.2% | |
| Total equity incl. non-controlling | 7.45B+13.5% | 6.57B-24.8% | 8.74B-9.1% | 9.62B-29.7% | 13.7B+38.5% | |
| Total liabilities & equity | 10.6B+12.9% | 9.36B-23.9% | 12.3B-8.9% | 13.5B-24.1% | 17.8B+37.2% | |
| Treasury shares | 3.28M+45.3% | 2.25M+29.0% | 1.75M+172.8% | 640K | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 532M+16.9% | 455M+21.4% | 375M+92.8% | 194M-71.0% | 669M+14.4% | ||
| Depreciation & amortization | 165M+9.1% | 152M+3.9% | 146M+6.3% | 137M-0.2% | 138M-0.7% | |
| Intangible amortization | 23.8M+12.3% | 21.2M-10.9% | 23.8M-4.4% | 24.9M-12.3% | 28.4M+3.3% | |
| Share-based compensation | 58.0M-6.9% | 62.3M+1.6% | 61.3M+0.7% | 60.9M+18.9% | 51.2M+23.1% | |
| Deferred income taxes | 171M+127.2% | -627M-94.3% | -323M+74.0% | -1.24B-214.4% | 1.08B+10.5% | |
| Change in receivables | -19.6M-21.0% | -16.2M-42.1% | -11.4M-113.0% | 87.4M+328.4% | 20.4M+36.0% | |
| Change in inventory | -68.9M-710.6% | -8.50M-118.4% | 46.3M-70.8% | 159M+444.5% | -46.1M-188.5% | |
| -190M-18.4% | -160M-893.1% | 20.2M+101.7% | -1.21B-51.4% | -797M-1040.8% | ||
| Capital expenditure | 158M-4.8% | 166M+5.7% | 157M+38.9% | 113M-15.7% | 134M+23.2% | |
| Free cash flow | 375M+29.4% | 290M+32.7% | 218M+167.4% | 81.6M-84.8% | 536M+12.4% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 669M-47.6% | 1.28B+85.3% | 689M-66.6% | 2.06B+141.9% | 852M+242.8% | |
| Sales/maturities of investments | 62.0M-68.9% | 199M-44.8% | 361M+1.0% | 358M+4.8% | 341M+22.6% | |
| Proceeds from sale of PP&E | 100K+0.0% | 100K-50.0% | 200K+0.0% | 200K+284.6% | 52.0K-25.7% | |
| Other investing activities | — | 0.00 | 0.00-100.0% | 1.50M | 0.00+100.0% | |
| -283M-29.4% | -219M+48.6% | -426M-143.7% | 974M+1856.5% | -55.4M+89.4% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00-100.0% | 1.19B | 0.00 | |
| Long-term debt repaid | 500K+25.0% | 400K-20.0% | 500K+0.0% | 500K-83.4% | 3.02M-99.3% | |
| Common stock issued | — | — | — | 3.40M+283.8% | -1.85M-125.5% | |
| Common stock repurchased | 296M+45.1% | 204M-52.5% | 429M+98.7% | 216M+331.4% | 50.0M-50.0% | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | — | — | — | — | -12.6M-201.7% | |
| Net change in cash | 42.4M-50.4% | 85.4M+383.7% | -30.1M+17.8% | -36.6M+81.3% | -196M-4490.3% | |
| Interest paid | 46.6M+0.2% | 46.5M-2.1% | 47.5M+94.7% | 24.4M+984.0% | 2.25M-89.6% | |
| Income taxes paid | 61.6M-38.0% | 99.4M-23.3% | 130M-18.1% | 158M+17.5% | 135M+106.4% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 8.18B-11.1% | 9.20B-2.2% | 9.41B-25.0% | 12.5B-44.5% | 22.6B+30.0% | |
| P/E | 10.8× | — | — | — | 5.3×+16.5% | |
| P/S | 3.2×-11.7% | 3.6×+3.6% | 3.5×-22.6% | 4.5×-42.2% | 7.7×+13.2% | |
| P/B | 1.1×-21.7% | 1.4×+25.3% | 1.1×-24.6% | 1.5×-10.2% | 1.7×-6.2% | |
| P/FCF | 21.8×-31.3% | 31.8×-24.3% | 42.0×-49.3% | 82.8×+96.2% | 42.2×+15.6% | |
| Earnings yield | 9.3% | — | — | — | 18.8%-14.2% | |
| FCF yield | 4.6%+45.5% | 3.1%+32.1% | 2.4%+97.3% | 1.2%-49.0% | 2.4%-13.5% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Fiscal year | CEO | Total, as reported | Actually paid | Other executives, average | $100 in the stock | $100 in peers |
|---|---|---|---|---|---|---|
| FY2025 | Norman Schwartz | $8M | $7.3M | $3M | — | — |
| FY2024 | Norman Schwartz | $8.3M | $8.6M | $3.1M | — | — |
| FY2023 | Norman Schwartz | $7.5M | $1M | $2.5M | — | — |
| FY2022 | Norman Schwartz | $7.5M | −$5.6M | $2.6M | — | — |
| FY2021 | Norman Schwartz | $8.7M | $20.4M | $3.2M | $129.61 | $138.73 |
| FY2020 | Norman Schwartz | $8M | $21.3M | $2.8M | — | — |
From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.
Source: BIO’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all BIO filings on SEC EDGAR → Not investment advice.
